Yuki Horibe
Suita, 5650871, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility.
Journal: Japanese journal of clinical oncology
Published: May 27, 2026
Prognostic significance of the FAN score in patients with advanced urothelial carcinoma treated with enfortumab vedotin monotherapy.
Journal: Japanese journal of clinical oncology
Published: May 11, 2026
Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma.
Journal: Scientific reports
Published: April 02, 2026
Microbiome-Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers.
Journal: Cancer science
Published: April 01, 2026
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma.
Journal: Cancer treatment and research communications
Published: March 26, 2026
Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: November 20, 2025
Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer.
Journal: Cancer science
Published: August 13, 2025
Multi-Regional Profiling of Epidermal Growth Factor Receptor L858R Mutation-Positive Metastatic Renal Pelvic Cancer Successfully Treated With Osimertinib.
Journal: JCO precision oncology
Published: August 06, 2025
Last Updated: 09/26/2026